Maytansine is a pharmacologically active 19-membered ansamacrolide derived from
various medicinal plants and microorganisms. Among the most studied pharmacological …

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human
clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of …

Maytansinoid conjugates are currently under different phases of clinical trials and have been
showing promising activity for various types of cancers. In this study, we have elucidated the …

Maytansine, a potent clinically evaluated plant‐derived anti‐tumor drug, and its microbial
counterpart, ansamitocin P‐3, showed a substantially higher cytoxicity than many other anti …

Maytansine (1) and its congeners have been isolated from higher plants, mosses and from
an Actinomycete, Actinosynnema pretiosum. The ansamitocins P-1 to P-4 (11b–11e) are …

Maytansine is a potent microtubule-targeted compound that induces mitotic arrest and kills
tumor cells at subnanomolar concentrations. However, its side effects and lack of tumor …

Synthetic derivatives of the microtubule-targeted agent maytansine, commonly known as
drug maytansinoids or DMs, are emerging as potential cancer therapeutics. DM1 is an …

We report the structural optimization of tanshinone IIA, a natural product which possesses
anti-tumor properties but low water-solubility, weak antiproliferative activity and poor PK …

A phase II evaluation of MAYT was performed in patients with advanced lung cancer, the
majority of whom had had prior chemotherapy and poor PS. The overall tumor regression …

Drug resistance is one of the major obstacles for successful chemotherapy of malignant
tumors including cervical cancer. To overcome this problem, a lot of efforts have been made …